Solutions for Autoimmune Disease Drug Development

The immune system's fundamental function depends on exquisitely regulated self-antigen recognition and tolerance mechanisms - the cornerstone of immunological homeostasis. This critical balance is maintained through complementary central tolerance (clonal deletion in thymus/bone marrow) and peripheral tolerance. However, when the immune system faces "immune warning signals", this balance may be threatened, increasing the risk of potential Autoimmune Disease (AIDs). According to statistics, about 10% of healthy individuals have detectable low levels of autoantibodies in their serum. These antibodies, though not causing noticeable symptoms, indicate a potential risk mechanism of immune imbalance.

Click to view ACROBiosystems Solutions for AIDs Drug Development

"Where Proteins and lnnovation Advance Biomedicine", ACROBiosystems collaborates with leading global pharmaceutical companies to provide comprehensive solutions for AIDs drug development. Our integrated portfolio encompasses high-quality biological reagents including recombinant proteins, antibodies, engineered cell lines, specialized assay kits and organoids, as well as one-stop services. We support the entire drug development process through integrated services spanning from drug discovery and development, manufacturing and quality control to preclinical and clinical studies.

ACROBiosystems' comprehensive drug development solutions

>> Discover ComboX – A Combination of Universal Solutions

1. Dunleavy KA, Raffals LE, Camilleri M. Intestinal barrier dysfunction in inflammatory bowel disease: underpinning pathogenesis and therapeutics. Digestive diseases and sciences. 2023, 68 (12):4306-20. https://doi.org/10.1007/s10620-023-08122-w

2. Guo J, Zhang H, Lin W, et al. Signaling pathways and targeted therapies for psoriasis[J]. Signal transduction and targeted therapy, 2023, 8(1): 437. https://doi.org/10.1038/s41392-023-01655-6

3. Ding Q, Hu W, Wang R, et al. Signaling pathways in rheumatoid arthritis: implications for targeted therapy[J]. Signal transduction and targeted therapy, 2023, 8(1): 68. https://doi.org/10.1038/s41392-023-01331-9

4. Huang I H, Chung W H, Wu P C, et al. JAK–STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review[J]. Frontiers in immunology, 2022, 13: 1068260. https://doi.org/10.3389/fimmu.2022.1068260

5. Podbielska M, O’Keeffe J, Pokryszko-Dragan A. New insights into multiple sclerosis mechanisms: lipids on the track to control inflammation and neurodegeneration[J]. International journal of molecular sciences, 2021, 22(14): 7319. https: //doi.org/10.3390/ijms22147319

6. Akhil A, Bansal R, Anupam K, et al. Systemic lupus erythematosus: Latest insight into etiopathogenesis[J]. Rheumatology International, 2023, 43(8): 1381-1393. https://doi.org/10.1007/s00296-023-05346-x

7. Zhang Y, Liu W, Lai J, et al. Genetic associations in ankylosing spondylitis: circulating proteins as drug targets and biomarkers[J]. Frontiers in Immunology, 2024, 15: 1394438. https://doi.org/10.3389/fimmu.2024.1394438

8. Warshauer J T, Bluestone J A, Anderson M S. New frontiers in the treatment of type 1 diabetes[J]. Cell metabolism, 2020, 31(1): 46-61. https://doi.org/10.1016/j.cmet.2019.11.017

9. Srivastava A, Makarenkova H P. Innate immunity and biological therapies for the treatment of Sjögren’s syndrome[J]. International journal of molecular sciences, 2020, 21(23): 9172. https: //doi.org/10.3390/ijms21239172

10. Iorio R. Myasthenia gravis: the changing treatment landscape in the era of molecular therapies[J]. Nature Reviews Neurology, 2024, 20(2): 84-98. https://doi.org/10.1038/s41582-023-00916-w